Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
Panelists discuss how clinical trial data from CARTITUDE-1, CARTITUDE-4, and KarMMa-3 demonstrate the efficacy of CAR T therapies cilta-cel and ide-cel in multiple myeloma, comparing their real-world outcomes and considering patient-specific factors for treatment selection.
EP: 1.A High-Risk Myeloma Patient’s Path to CAR T: Personal and Clinical Perspectives
EP: 2.Behind the Scenes: Patient Education and Decision-Making for CAR T
EP: 3.Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
EP: 4.The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
EP: 5.From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
EP: 6.The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
EP: 7.Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Video content above is prompted by the following:
- Let’s start by discussing the treatment landscape and data with CAR T therapy in multiple myeloma. Please highlight pivotal data:
- CARTITUDE-1/CARTITUDE-4
- KarMMa-3
- In which patients do you consider cilta-cel vs ide-cel? Has real-world practice reflected efficacy and safety data from these trials?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
